Mar 2, 2023
Marijuana stocks don’t seem to be making the big headlines they used to. But that doesn’t mean the green wave has stopped.
Don't miss
- 'Hold onto your money': Jeff Bezos issued a financial warning, says you might want to rethink buying a 'new automobile, refrigerator, or whatever' — here are 3 better recession-proof buys
- UBS says 61% of millionaire collectors allocate up to 30% of their overall portfolio to this exclusive asset class
- Rich young Americans have lost confidence in the stock market — and are betting on these 3 assets instead. Get in now for strong long-term tailwinds
In fact, it's easier than ever to — legally — access marijuana. As of 2022, 21 states and the District of Columbia offer legal recreational cannabis to their residents. That means, according to Pew Research Center, that 43% of U.S. adults now live in an area that has legalized marijuana use.
But maybe it’s not your thing. Still, there could be some green in it for you. If you don’t care to take a toke, why not let cannabis puff up your portfolio instead?
Thanks for subscribing!
Read the best of Moneywise in 5 minutes or less.
By signing up, you accept Moneywise Terms of Use, Subscription Agreement, and Privacy Policy.
Here’s a look at three marijuana stocks ready to capitalize on the growing trend towards legalization. They’re listed on stock exchanges in Canada but trade over the counter in the U.S. — and analysts also see major upside in this trio.
Must Read
- The ultra-rich use these 5 real estate strategies to build wealth while they sleep — you can start with just $100
- Here’s the average income of Americans by age in 2026. Are you keeping up or falling behind?
- Insurance companies profit most from drivers who auto-renew without shopping around. Comparing 100+ quotes takes 2 minutes and costs nothing
Join 250,000+ readers and get Moneywise’s best stories and exclusive interviews first — clear insights curated and delivered weekly. Subscribe now.
Trulieve Cannabis Corp (TCNNF)
Trulieve Cannabis entered the cannabis industry by winning the first medical marijuana application in Florida in 2015. Today, it has 100 stores in the Sunshine State, and around 180 operated and affiliated dispensaries nationwide.
Advertisement
The company claims that it has leading market positions not just in Florida, but also in Arizona and Pennsylvania.
Trulieve’s financials have grown tremendously, and even the COVID-19 pandemic couldn’t stop the momentum. In 2020, revenue rose 106% from the 2019 level to $521.5 million.
In 2021, revenue surged another 80% to $938.4 million.
According to the latest earnings report, Trulieve earned $300.8 million of revenue in Q3 of 2022, up 34% year over year.
The stock, however, has plunged nearly 70% over the last 12 months.
Canaccord analyst Derek Dley sees a rebound on the horizon. The analyst has a ‘buy’ rating on Trulieve and a price target of C$50 on its Canada-listed shares — implying a potential upside of 488%.
Green Thumb Industries (GTBIF)
Green Thumb is a vertically integrated cannabis company headquartered in Chicago. It has 18 cultivation and manufacturing facilities, six consumer product brands, 77 open retail locations, and operations in 15 U.S. markets.
Advertisement
Just like Trulieve, Green Thumb stock hasn’t been a hot commodity: shares are down more than 50% in the last year.
Business, however, is still on the rise.
Read more: Here's how much the average American 60-year-old holds in retirement savings — how does your nest egg compare?
In 2022, the company generated $1.0 billion of revenue, representing a 13.9% increase year over year.
Advertisement
Stifel analyst Andrew Partheniou has a ‘buy’ rating on Green Thumb and a price target of C$30 on its Canada-listed shares. Since these shares trade at C$11.20 right now, the price target represents a potential upside of 168%.
Curaleaf Holdings (CURLF)
With a market cap of around $3.1 billion CAD, Curaleaf is a bigger company than both Trulieve and Green Thumb.
It has a huge presence in the U.S. cannabis industry, with 29 cultivation sites, approximately 4.4 million square feet of cultivation capacity, 148 retail locations and around 2,200 wholesale partner accounts.
In Q3 of 2022, revenue grew 7% year over year to $340 million.
Still, this pot heavyweight is not immune to the industry-wide sell-off as shares are down about 42% over the last six months.
Alliance Global Partners analyst Aaron Grey has a ‘buy’ rating on Curaleaf and a price target of C$12 on its Canada-listed shares — roughly 136% above where they sit today.
What to read next
- You could be the landlord of Walmart, Whole Foods and CVS (and collect fat grocery store-anchored income on a quarterly basis)
- The US dollar has lost 98% of its purchasing power since 1971 — invest in this stable asset before you lose your retirement fund
- Americans are paying nearly 40% more on home insurance compared to 12 years ago — here's how to spend less on peace of mind
You May Also Like
- JP Morgan sees gold hitting $6,000/oz before 2027 — and a Gold IRA lets you hold the physical metal while deferring the tax bill. Get your free guide from Priority Gold
- Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake — here’s what it is and the simple steps to fix it ASAP
- Thanks to Jeff Bezos, you can now become a landlord for as little as $100 — and no, you don't have to deal with tenants or fix freezers. Here's how
- Millionaires under 43 are reshaping investing — just 25% of their portfolios are in stocks. Here’s where their money is going
Jing is an investment reporter for Moneywise. He is an avid advocate of investing for passive income. Despite the ups and downs he’s been through with the markets, Jing believes that you can generate a steadily increasing income stream by investing in high quality companies.
